Knight Therapeutics Inc. (TSE:GUD) Director Samira Sakhia Purchases 20,000 Shares

Knight Therapeutics Inc. (TSE:GUD) Director Samira Sakhia bought 20,000 shares of Knight Therapeutics stock in a transaction on Monday, November 11th. The shares were purchased at an average cost of C$5.15 per share, for a total transaction of C$103,000.00.

Knight Therapeutics Price Performance

Shares of GUD traded down C$0.11 during mid-day trading on Monday, reaching C$5.15. The company had a trading volume of 89,720 shares, compared to its average volume of 67,522. Knight Therapeutics Inc. has a twelve month low of C$4.98 and a twelve month high of C$6.23. The company has a debt-to-equity ratio of 7.62, a current ratio of 3.41 and a quick ratio of 1.79. The company’s 50-day moving average is C$5.74 and its 200-day moving average is C$5.75. The company has a market capitalization of C$521.23 million, a P/E ratio of -26.30, a P/E/G ratio of -1,013.50 and a beta of 0.50.

Knight Therapeutics (TSE:GUD) last announced its quarterly earnings data on Thursday, August 8th. The company reported C($0.02) EPS for the quarter, missing analysts’ consensus estimates of C$0.03 by C($0.05). The firm had revenue of C$95.57 million during the quarter, compared to the consensus estimate of C$89.83 million. Knight Therapeutics had a negative net margin of 6.28% and a negative return on equity of 2.70%. On average, equities analysts anticipate that Knight Therapeutics Inc. will post 0.1009486 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts have weighed in on GUD shares. Stifel Nicolaus raised Knight Therapeutics from a “hold” rating to a “buy” rating and lifted their target price for the company from C$5.75 to C$6.75 in a research note on Tuesday, August 13th. Stifel Canada upgraded Knight Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Monday, August 12th.

About Knight Therapeutics

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.